From the Journals

Pot peaks in breast milk 1 hour after smoking


 

FROM OBSTETRICS & GYNECOLOGY

The levels of delta-9-tetrahydrocannabinol in breast milk peak around 1 hour after smoking, according to a pilot pharmacokinetic study.

Eight mothers who were either occasional or chronic cannabis smokers, and who exclusively breastfed their infants, were directed to smoke a preweighed, standardized amount of “Prezidential Kush” from a preselected Denver dispensary after initially discontinuing for 24 hours. Researchers collected breast milk samples from just before smoking, and at 20 minutes, 1 hour, 2 hours, and 4 hours after smoking, according to a paper published in the May issue of Obstetrics & Gynecology.

Marijuana leaves Smithore
The mean concentration of delta-9-tetrahydrocannabinol in the breast milk peaked at 94 ng/mL at 1 hour after smoking, and the average concentration over the whole period was 53.5 ng/mL.

This translated to an estimated relative infant dose of 2.5% of the maternal dose, or 8 mcg per kilogram per day.

“It remains unclear what exposure to cannabis products during this critical neurobehavioral development period will mean for the infant,” wrote Teresa Baker, MD, of Texas Tech University Health Sciences Center, and her coauthors. “These questions will require an enormous effort to determine.”

Concentrations of delta-9-tetrahydrocannabinol metabolites 11-OH-delta-9-tetrahydrocannabinol and 11-Nor-9-carboxy-delta-9-tetrahydrocannabinol were too low to be detected.

The authors noted that these metabolites are known to be more water soluble and polar than delta-9-tetrahydrocannabinol itself, which may make it more difficult for them to enter the breast milk compartment.

Pages

Recommended Reading

Tackling opioids and maternal health in US Congress
MDedge ObGyn
2018 Update on prenatal carrier screening
MDedge ObGyn
Metformin reduces preterm births, late miscarriages in PCOS
MDedge ObGyn
ACOG: Ob.gyns. can help protect pregnant women’s workplace rights
MDedge ObGyn
Statins, ACE inhibitors linked to fetal cardiac anomalies
MDedge ObGyn
Reassurance for women taking certolizumab during pregnancy
MDedge ObGyn
SSRI exposure in utero may change brain structure and connectivity
MDedge ObGyn
Pregnant women in clinical trials: FDA questions how to include them
MDedge ObGyn
Zika virus: Sexual contact risk may be limited to short window
MDedge ObGyn
Does measuring episiotomy rates really benefit the quality of care our patients receive?
MDedge ObGyn